Regulatory evaluation of biosimilars throughout their product life-cycle

Hye-Na Kang & Ivana Knezevic

Abstract

The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference products and are usually developed after patents on the original products have expired. Their introduction into the market is likely to reduce the costs of medicines substantially, thereby improving the availability of treatment for patients. However, there are barriers to market access for biosimilars. This article discusses the factors that give rise to these barriers and explains the importance of regulatory oversight throughout the product life-cycle of biosimilars. The paper also describes the role regulators can play in increasing confidence in biosimilars use by: (i) establishing regulatory oversight of biosimilars throughout their life-cycle, from development to post-licensing oversight, and ensuring that only high-quality, safe and efficacious biosimilars are available on the market; (ii) ensuring regulatory authorities have adequate capacity to assess and monitor the quality, safety and efficacy of biosimilars throughout their life-cycle; and (iii) monitoring the use of biosimilars in public health systems in collaboration with other stakeholders.

Introduction

Countries around the world face the common problems of an aging population and the associated increase in the prevalence of chronic diseases. The success of biotherapeutic products, such as such as large complex proteins, for treating human diseases, in the treatment of many life-threatening chronic conditions, combined with the approaching expiry of patent protection on these products, has led to increased interest in the development of biosimilars, which are products that are similar to the originals. The patents of many best-selling biotherapeutic products have already expired or will soon reach their expiry date. For example, the patent on the breast cancer drug Herceptin, a monoclonal antibody with international proprietary name
trastuzumab, expired in July 2014 in the European Union and will expire in June 2019 in the United States of America.¹ Currently, several companies worldwide have developed biosimilar versions of trastuzumab. The development of biosimilars after the expiry of patents on the original products is expected to make biotherapeutics available at more affordable prices and to increase their use by providing more treatment options. European Union countries have the longest history of using biosimilars and it is expected that, as a result, these countries’ healthcare systems could save 11.8 to 33.4 billion euros between 2007 and 2020.² A recent report concluded that competition from biosimilars has led to a consistent reduction in the average price of treatment in clinical areas where they have been introduced and that, in some countries, patients began to have access to product classes that were previously unavailable.³

In its guidelines on the evaluation of similar biotherapeutic products, the World Health Organization (WHO) defines a similar biotherapeutic product (also called a biosimilar) as a “biotherapeutic product that is similar in terms of quality, safety and efficacy to an already licensed reference product”.⁴ Examples of biosimilars include growth hormone, erythropoietin and monoclonal antibodies for the treatment of a wide range of diseases.

Biotherapeutic products are generally relatively large and complex entities that are more difficult to characterize than simpler, chemical drugs. They are a heterogeneous group of proteins whose structures are sensitive both to the inherent variability of the protein production, or expression, system and to changes in manufacturing processes. Thus, no biotherapeutic product or biosimilar can be scientifically or technically identical the originator’s product. Nor can it be identical to the different version of itself that is produced after a change in manufacturing process. In fact, this is also true for different batches of the same product. Consequently, if these biological substances are to be used routinely in clinical practice, it is essential that different production lots are of consistent quality. Therefore establishing robust manufacturing and quality control procedures, many of which may be in-process controls carried out during manufacturing, is needed.⁵

In May 2014, the sixty-seventh World Health Assembly adopted a resolution on access to biotherapeutic products and on ensuring their quality, safety and efficacy.⁶ Since then, action has been taken to help WHO Member States to increase their expertise in evaluating biosimilars and expand their capacity to do so; to improve regulatory convergence; and to use existing resources more effectively. As part of its biological standardization programme, WHO provides written
guidelines on the evaluation of biological products (including biosimilars) to ensure their quality, safety and efficacy. These guidelines are usually incorporated into national requirements to ensure that the products produced and used in a country conform to current international standards, such standards are published as recommendations in WHO’s Technical Report Series. In addition, regulatory guidance documents produced by WHO also provide advice for national regulatory authorities and manufacturers on the evaluation of biological products, with the aim of establishing a harmonized regulatory framework for products available on international markets. The current regulatory framework for biosimilars has been successful in enabling many biosimilar products to gain regulatory approval around the world.

However, there are barriers to market access for biosimilars. One is the belief of many clinicians that a similar biotherapeutic product cannot be as good as the original for their patients. More precisely, there is a lack of understanding that biosimilars have undergone comparability studies that demonstrate their similarity, that data on the original products can be extrapolated and that biosimilars become independent products after licensing and undergo their own development. This article discusses the factors that give rise to these barriers and explains the role of regulators and the importance of regulatory oversight throughout the product life-cycle of biosimilars, both of which are critical for increasing confidence in their use. In addition, WHO’s role in improving regulatory convergence at the global level by developing standards and helping ensure these standards are incorporated into national regulatory requirements is explained briefly.

**Life-cycle and regulatory evaluation**

Like other biological medicines, biosimilars have a product life-cycle, which starts with research and development and continues through manufacturing to regulatory evaluation of quality, safety and efficacy for both licensing and post-licensing oversight. However, the life-cycle of a biosimilar is unique in the sense that its regulatory approval relies on the safety and efficacy data and knowledge gained during the development and licensing of an originator, or reference, product. However, once licensed, the biosimilar becomes an individual product and post-licensing evaluation should be carried out as for any other biological product.

The safety and efficacy of a biosimilar is established by demonstrating its similarity to a reference product. The concept of extrapolating data that is used the licensure of biosimilars is not new to regulators or manufacturers, it is an established scientific and regulatory principle that
has been exercised for many years, for example, in considering changes to manufacturing processes of the originator biologicals.\textsuperscript{7,10} Regulators have learned how much variation is acceptable between different versions of a product from their experience with postapproval manufacturing changes. Prescribers, such as physicians and clinicians, tend to judge the safety and efficacy of medicines using clinical trial data. Although clinical data is important, it is a mistake to overlook the extensive data on the characteristics of a medicine derived using the state-of-the-art, comparative, analytical methods that underlie biosimilar development programmes.\textsuperscript{10} Usually, analytical assessments are more sensitive for detecting differences between, or changes in, products than the endpoints used in clinical trials (i.e. the clinical outcomes measured objectively to determine whether the intervention is beneficial or not). Thus, a biosimilar with chemical, physical and biological attributes that are highly similar to those of the reference product would be expected to have the same pharmacological characteristics as the reference product and a similar safety and efficacy profile for every clinical indication.

Manufacturing processes are often altered after regulatory approval and medicines can undergo changes during their product life-cycle. Reasons for these changes include: improvements in the manufacturing process; an increase in the scale of production; movement to a new manufacturing site; improvements in product stability; and the need to comply with new regulatory requirements.\textsuperscript{7,8} Such changes are welcome as they often represent improvements. However, a minor alteration in the manufacturing process may have a large impact on the final product, which could, for example, lead to serious adverse effects in patients. For instance, a change in the formulation of erythropoietin resulted in an increase in the occurrence of pure red cell aplasia.\textsuperscript{11} Thus, any change in the manufacturing processes of a licensed medicine, particularly a biological, should be approved by the regulators once the medicines produced before and after the manufacturing change have been shown to be comparable in a comparability assessment.\textsuperscript{7} Although the general scientific principles of comparability assessments following changes in manufacturing processes are applicable to comparability assessments for biosimilars, more extensive and comprehensive data may be required for biosimilars than for other products. Once a biosimilar has been approved, there is no regulatory requirement for its biosimilarity to the reference product to be demonstrated again at any other time, the biosimilar effectively becomes a stand-alone product.\textsuperscript{7} After approval, therefore, the management of biosimilars throughout their life-cycle is the same as for other biologicals and, accordingly, biosimilars should be managed in a way that ensures their benefits outweigh their risks throughout their life-
cycle. In some cases, specific safety monitoring requirements that have been imposed on the reference product or product class should be incorporated into the biosimilar pharmacovigilance plan, unless there is compelling evidence not to do so.\(^4\) Recently, at the request of Member States, WHO has published new guidelines on postapproval changes to biotherapeutic products.\(^7,12\) In general, the guiding principles that apply to postapproval changes to biotherapeutic products also apply to postapproval changes to biosimilars.

Some countries have biotherapeutics on their markets that are claimed to be copies of original products (i.e. so-called non-innovator or copy-version products). These medicines have not been approved through a biosimilar approval procedure but have, instead, been licensed as generics or small-molecule medicines.\(^9\) However, as biotherapeutics are relatively large and complex proteins, procedures established for generics or small-molecule medicines are not suitable for the development, evaluation or licensing of biosimilars.\(^4\) As stated in WHO’s guidelines on the evaluation of similar biotherapeutic products, a biosimilar that has not been demonstrated to be similar to a reference product through head-to-head comparisons should not be described as similar or be called a biosimilar.\(^4\) These guidelines also stipulate that, “regular review of NRAs [national regulatory authorities] for their licensing, for adequacy of their regulations for providing oversight, and for the processes and policies that constitute the regulatory framework is an essential component of a well-functioning and up-to-date regulatory oversight for biotherapeutics”.\(^4\) If problems arise with products that were licensed before national regulations for biosimilars had been established, the regulatory authority should take action to identify the problematic products in its market, to assess the risk–benefit balance of their use and to decide whether additional evaluations are needed. Based on the results of these evaluations, some products may be removed from the market because of concerns about safety or efficacy. This step-wise approach to regulatory assessment is recommended by WHO and is intended to be flexible and to increase access to biotherapeutic products, including biosimilars of assured quality, safety and efficacy.\(^9\)

**Role of regulatory authorities**

Market access to biosimilars can be restricted by several of factors: (i) manufacturing processes may be expensive and complex; (ii) patents on the manufacturing processes of the original product may not have expired; (iii) biosimilar manufacturers may have limited access to data on the original product; (iv) appropriate regulatory frameworks may not be in place; and
(v) government policies on switching to biosimilars, pricing and reimbursement may be lacking. Experience with the introduction of small-molecule generic medicines showed that gaining the trust of all stakeholders, including policy-makers, regulators, physicians and other health-care providers, is essential for increasing the uptake of biosimilars. Governments should provide a robust regulatory framework; ensure intellectual property rights are respected; guarantee fair pricing; devise a policy on reimbursements and incentives; and ensure health-care professionals and patients are fully informed. In particular, it is important that other stakeholders understand the role played by regulatory authorities in ensuring better access to biosimilars. Regulators who review and approve biosimilars are in a very good position to provide reassurance about their use.

One of the main barriers to the uptake of biosimilars is the perception that, in general, they may not have been studied thoroughly enough and that, therefore, they may not be safe. This perception is due to a lack of knowledge about the scientific principles underlying the development and licensing of biosimilars and to the inappropriate labelling of non-innovator and copy-version products as biosimilars. Regulatory authorities should develop a specific, appropriate, regulatory framework for approving biosimilars that is distinct from the regulatory procedures previously applied to copy-version products, where regulatory evaluation was not well-defined. In addition, regulatory authorities should also make an effort to communicate with, and educate, all stakeholders, including patients, about biosimilars and their approval. The publication of public assessment reports on biosimilars and of the relevant regulations and guidelines could provide useful communication tools. The Biosimilar Working Group of the International Pharmaceutical Regulators Programme published a template for biosimilar assessment reports that could be used by regulators worldwide; it is entitled Public assessment summary information for biosimilars (PASIB). The provision of such information will contribute to better transparency and increase public trust in biosimilars.

Regulatory authorities could improve access to biosimilars by increasing the efficiency of their review processes and of regulatory evaluation, for example, by increasing their capacity and reducing the time needed, without compromising the quality of the review process. In addition, they should align national regulatory requirements with WHO’s guiding principles to avoid the need for bridging studies and to reduce development costs. Regulatory authorities, especially in countries with limited regulatory resources, should focus on activities that eliminate duplications of effort and add genuine value. WHO and International conference of drug regulatory
authorities recommend that joint, collaborative assessments should be carried out with neighbouring countries, where appropriate, and that efforts should be made to ensure that products that have already undergone rigorous evaluation in other countries are not evaluated again.\textsuperscript{12,15,16}

In 2017, WHO initiated discussions on a pilot project to prequalify two biosimilar monoclonal antibody products: (i) rituximab, which is principally used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukaemia; and (ii) trastuzumab, which is used to treat breast cancer. The purpose of the pilot study was to explore the possibility of assisting countries with limited expertise and resources to evaluate products such as these, thereby increasing access to biosimilars. Details of this pilot study and of associated issues are available in the report of an expert consultation held in Geneva, Switzerland in May 2017, which aimed to improve access to, and the use of, biosimilars.\textsuperscript{13}

Future of biosimilars

By competing with the originator’s biotherapeutic products, biosimilars provide alternative treatment options, thereby reducing the price of these biotherapeutics and increasing their availability. However, improving access to biosimilars and ensuring they are used appropriately requires a high degree of collaboration between all stakeholders, each of which has a distinct role. The main roles of regulatory authorities, for example, are to provide regulatory oversight of biosimilars throughout their product life-cycle and to ensure that only high-quality, safe and efficacious biosimilars are available on the market.\textsuperscript{12} To achieve this, the capacity of regulatory authorities should be increased.\textsuperscript{12} However, strengthening regulatory systems by increasing capacity will be particularly challenging in resource-limited settings. Regulatory authorities in these settings should consider establishing regulatory procedures that improve the efficiency of the approval process, approval could be based on a collaborative review carried out with other regulatory authorities or on a previous expert review carried out, for example, when another regulatory authority with the appropriate expertise granted approval. In addition, regulatory authorities should monitor the use of biosimilars in public health systems in collaboration with other stakeholders. To assist, WHO has established global standards to ensure the quality, safety and efficacy of biotherapeutics, including biosimilars, at all stages of their life-cycle.\textsuperscript{4,7–9} These standards could serve as a basis for mutual recognition of regulatory oversight and for regulatory convergence at the global level.
Competing interests:
None declared.

References


